SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75.0 million ...

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from the previous plan [1][2] Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1] - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1] - The new plan will expire on March 31, 2026, and the timing and number of shares repurchased will depend on market conditions and other factors [3] Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4] - The company plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5]

DISTRIBUTED-WORK-MODEL/OAKLAND, Calif.--(BUSINESS WIRE)--Block, Inc. (NYSE: XYZ) is hosting its 2025 Investor Day today, Wednesday, November 19, 2025, at 9:00 a.m. Pacific Time in San Francisco. During the event, senior leadership will present full-year 2026 financial guidance and a three-year financial outlook as well as a $5 billion increase to its stock repurchase program as part of the company's broader capital allocation strategy. A live webcast and replay of the event will be available at. ...

Core Viewpoint - Bank7 Corp. will release its financial results for Q3 2025 on October 15, 2025, and will hold a conference call to discuss these results with investors [1]. Company Overview - Bank7 Corp. is a bank holding company based in Oklahoma City, operating through its subsidiary Bank7, with twelve locations across Oklahoma, the Dallas/Fort Worth area, and Kansas [3]. - The company focuses on serving business owners and entrepreneurs by providing fast and well-designed loan and deposit products [3]. - Bank7 Corp. aims for organic growth by selectively opening new branches in target markets and pursuing strategic acquisitions [3]. Financial Announcements - A conference call will take place on October 15, 2025, at 9:00 a.m. CST, where investors can participate by dialing 1-888-348-6421 or accessing it online [1]. - An archive of the webcast will be available for one year after the call for those unable to attend live [2].

Core Viewpoint - RBB Bancorp has authorized a stock repurchase plan for up to $18 million of its outstanding common stock, effective through June 30, 2026, indicating a commitment to returning value to shareholders [1][2]. Company Overview - RBB Bancorp is a community-based financial holding company headquartered in Los Angeles, California, with total assets of $4.0 billion as of March 31, 2025 [3]. - The company's subsidiary, Royal Business Bank, operates 24 full-service branches across six states, primarily serving Asian-centric communities [3]. - The bank offers a variety of services including consumer and business banking, commercial loans, and wealth management [3]. Stock Repurchase Plan Details - The repurchase plan allows for shares to be bought in open market or private transactions, and can be suspended or modified based on various factors such as market conditions and liquidity [2]. - The plan does not obligate the company to repurchase a specific number of shares, providing flexibility in execution [2].

Core Points - Mission Bancorp has extended its stock repurchase plan and approved a 5.00% stock dividend, reflecting the company's strong performance amid uncertainty [1][2] - The stock repurchase plan allows for a maximum of $3.0 million in common stock to be repurchased, with an extension through October 23, 2025 [2] - The 5.00% stock dividend will be issued on June 2, 2025, to shareholders of record as of May 19, 2025 [3] Company Overview - Mission Bancorp has $1.9 billion in assets and operates four wholly owned subsidiaries, including Mission Bank [4] - The company serves various regions in California through eight Business Banking Centers [4]

Core Viewpoint - OraSure Technologies, Inc. has authorized a stock repurchase program of up to $40 million over the next twenty-four months, to be funded from cash on hand [1][2]. Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions, aiming to improve access, quality, and value of healthcare through innovative testing and sample management [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., develops, manufactures, and distributes rapid diagnostic tests and sample collection devices globally [3]. Stock Repurchase Program - The stock repurchase may be executed through various methods in compliance with applicable laws, with the timing and amount determined at the management's discretion [2]. - The repurchase program can be modified, suspended, or discontinued at any time without prior notice [2].